logo-loader

Metal Tiger’s Kalahari Metals receives Botswana government approval for Ngami EMP

Published: 06:41 03 Apr 2019 EDT

Botswana thumbs up
Kalahari has also submitted three other EMPs for other projects in Botswana

Metal Tiger PLC’s (LON:MTR) Kalahari Metals Limited (KML) has received approval from the Botswana government for an environmental management plan (EMP) at its Ngami copper project.

AIM-listed Metal Tiger, which holds a 50% stake in KML, said the EMP would now be subject to a four-week public review period, a precursor to authorisation which, if granted, would allow drilling at “compelling” targets at Ngami.

READ: Metal Tiger roars as MOD Resources releases T3 copper project feasibility study

The group added that an EMP for KML’s Okavango copper project (OCP), located North East of Ngami, had been resubmitted to the government following feedback from the Department of Environmental Affairs (DEA).

Elsewhere, EMPs had also been submitted for the Kitlanya East and Kitlanya West projects following news in early March that sampling results and historical data had identified compelling targets for drill testing.

READ: Metal Tiger says recent data for the Kitlanya copper project has provided compelling targets for drill testing

EMPs usually cover the design, construction, commissioning, and operation of projects as well as any environmental issues that could arise and how to manage them.

"I am delighted by the continued support that the Botswana Department of Environmental Affairs has shown for the development of the KML portfolio, in which we see significant potential”, said Michael McNeilly, chief executive of Metal Tiger.

He added that the KML portfolio now included “a number of exciting geophysical and structural targets” which warranted further drilling.

Shares were up 0.4% at 1.36p in late-morning trading on Wednesday.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

57 minutes ago